Literature DB >> 25660826

Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic Review.

Shannon M Smith1, Florence Paillard2, Andrew McKeown3, Laurie B Burke4, Robert R Edwards5, Nathaniel P Katz6, Elektra J Papadopoulos7, Bob A Rappaport7, Ashley Slagle7, Eric C Strain8, Ajay D Wasan9, Dennis C Turk10, Robert H Dworkin11.   

Abstract

UNLABELLED: Measurement of inappropriate medication use events (eg, abuse or misuse) in clinical trials is important in characterizing a medication's abuse potential. However, no gold standard assessment of inappropriate use events in clinical trials has been identified. In this systematic review, we examine the measurement properties (ie, content validity, cross-sectional reliability and construct validity, longitudinal construct validity, ability to detect change, and responder definitions) of instruments assessing inappropriate use of opioid and nonopioid prescription medications to identify any that meet U.S. and European regulatory agencies' rigorous standards for outcome measures in clinical trials. Sixteen published instruments were identified, most of which were not designed for the selected concept of interest and context of use. For this reason, many instruments were found to lack adequate content validity (or documentation of content validity) to evaluate current inappropriate medication use events; for example, evaluating inappropriate use across the life span rather than current use, including items that did not directly assess inappropriate use (eg, questions about anger), or failing to capture information pertinent to inappropriate use events (eg, intention and route of administration). In addition, the psychometric data across all instruments were generally limited in scope. A further limitation is the heterogeneous, nonstandardized use of inappropriate medication use terminology. These observations suggest that available instruments are not well suited for assessing current inappropriate medication use within the specific context of clinical trials. Further effort is needed to develop reliable and valid instruments to measure current inappropriate medication use events in clinical trials. PERSPECTIVE: This systematic review evaluates the measurement properties of inappropriate medication use (eg, abuse or misuse) instruments to determine whether any meet regulatory standards for clinical trial outcome measures to assess abuse potential.
Copyright © 2015 American Pain Society. All rights reserved.

Entities:  

Keywords:  Abuse potential; clinical trial; measurement properties; misuse

Mesh:

Year:  2015        PMID: 25660826      PMCID: PMC5460153          DOI: 10.1016/j.jpain.2015.01.009

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  53 in total

1.  Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial.

Authors:  Robert N Jamison; Edgar L Ross; Edward Michna; Li Q Chen; Caroline Holcomb; Ajay D Wasan
Journal:  Pain       Date:  2010-03-23       Impact factor: 6.961

2.  Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index.

Authors:  John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch
Journal:  Drug Alcohol Depend       Date:  2006-10-11       Impact factor: 4.492

3.  Evidence for a drug dependence syndrome among narcotic users.

Authors:  H A Skinner; A E Goldberg
Journal:  Br J Addict       Date:  1986-08

4.  Addiction rare in patients treated with narcotics.

Authors:  J Porter; H Jick
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

5.  Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM).

Authors:  Ellen C Meltzer; Denis Rybin; Richard Saitz; Jeffrey H Samet; Sonia L Schwartz; Stephen F Butler; Jane M Liebschutz
Journal:  Pain       Date:  2010-12-21       Impact factor: 6.961

6.  Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Authors:  Sandra D Comer; James P Zacny; Robert H Dworkin; Dennis C Turk; George E Bigelow; Richard W Foltin; Donald R Jasinski; Edward M Sellers; Edgar H Adams; Robert Balster; Laurie B Burke; Igor Cerny; Robert D Colucci; Edward Cone; Penney Cowan; John T Farrar; David J Haddox; Jennifer A Haythornthwaite; Sharon Hertz; Gary W Jay; Chris-Ellyn Johanson; Roderick Junor; Nathaniel P Katz; Michael Klein; Ernest A Kopecky; Deborah B Leiderman; Michael P McDermott; Charles O'Brien; Alec B O'Connor; Pamela P Palmer; Srinivasa N Raja; Bob A Rappaport; Christine Rauschkolb; Michael C Rowbotham; Cristina Sampaio; Beatrice Setnik; Marta Sokolowska; Joseph W Stauffer; Sharon L Walsh
Journal:  Pain       Date:  2012-09-19       Impact factor: 6.961

7.  Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness.

Authors:  S A Maisto; M P Carey; K B Carey; C M Gordon; J R Gleason
Journal:  Psychol Assess       Date:  2000-06

8.  Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.

Authors:  Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison
Journal:  J Pain Symptom Manage       Date:  2004-09       Impact factor: 3.612

9.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

10.  Screening mothers of young children for substance abuse.

Authors:  K J Kemper; A Greteman; E Bennett; T R Babonis
Journal:  J Dev Behav Pediatr       Date:  1993-10       Impact factor: 2.225

View more
  9 in total

1.  Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Authors:  Shannon M Smith; Judith K Jones; Nathaniel P Katz; Carl L Roland; Beatrice Setnik; Jeremiah J Trudeau; Stephen Wright; Laurie B Burke; Sandra D Comer; Richard C Dart; Raymond Dionne; J David Haddox; Jerome H Jaffe; Ernest A Kopecky; Bridget A Martell; Ivan D Montoya; Marsha Stanton; Ajay D Wasan; Dennis C Turk; Robert H Dworkin
Journal:  J Pain       Date:  2017-05-04       Impact factor: 5.820

Review 2.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

3.  Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain.

Authors:  Martin D Cheatle; Peggy A Compton; Lara Dhingra; Thomas E Wasser; Charles P O'Brien
Journal:  J Pain       Date:  2019-01-26       Impact factor: 5.820

4.  Independent association of tobacco use with opioid use disorder in patients of European ancestry with chronic non-cancer pain.

Authors:  Martin D Cheatle; Mary Falcone; Lara Dhingra; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2020-02-14       Impact factor: 4.492

5.  Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain.

Authors:  Martin D Cheatle; Rollin M Gallagher; Charles P O'Brien
Journal:  Pain Med       Date:  2018-04-01       Impact factor: 3.750

6.  Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.

Authors:  Ingrid A Binswanger; Deborah Rinehart; Shane R Mueller; Komal J Narwaney; Melanie Stowell; Nicole Wagner; Stan Xu; Rebecca Hanratty; Josh Blum; Kevin McVaney; Jason M Glanz
Journal:  J Gen Intern Med       Date:  2022-02-07       Impact factor: 6.473

7.  Personality to Prescription Drug Misuse in Adolescents: Testing Affect Regulation, Psychological Dysregulation, and Deviance Proneness Pathways.

Authors:  Sherry H Stewart; Annie Chinneck; Kara Thompson; Mohammad H Afzali; Raquel Nogueira-Arjona; Ioan T Mahu; Patricia J Conrod
Journal:  Front Psychiatry       Date:  2021-04-27       Impact factor: 4.157

8.  Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.

Authors:  Jennifer S Gewandter; Shannon M Smith; Robert H Dworkin; Dennis C Turk; Tong J Gan; Ian Gilron; Sharon Hertz; Nathaniel P Katz; John D Markman; Srinivasa N Raja; Michael C Rowbotham; Brett R Stacey; Eric C Strain; Denham S Ward; John T Farrar; Kurt Kroenke; James P Rathmell; Richard Rauck; Colville Brown; Penney Cowan; Robert R Edwards; James C Eisenach; McKenzie Ferguson; Roy Freeman; Roy Gray; Kathryn Giblin; Hanna Grol-Prokopczyk; Jennifer Haythornthwaite; Robert N Jamison; Marc Martel; Ewan McNicol; Michael L Oshinsky; Friedhelm Sandbrink; Joachim Scholz; Richard Scranton; Lee S Simon; Deborah Steiner; Kenneth Verburg; Ajay D Wasan; Kerry Wentworth
Journal:  Pain       Date:  2021-11-01       Impact factor: 7.926

9.  Opioid Pain Medication Prescription for Chronic Pain in Primary Care Centers: The Roles of Pain Acceptance, Pain Intensity, Depressive Symptoms, Pain Catastrophizing, Sex, and Age.

Authors:  Carmen Ramírez-Maestre; Ángela Reyes-Pérez; Rosa Esteve; Alicia E López-Martínez; Sonia Bernardes; Mark P Jensen
Journal:  Int J Environ Res Public Health       Date:  2020-09-03       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.